Cargando…
Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy – Six months follow-up result
BACKGROUND: Ischemic cardiomyopathy is a growing burden in third world countries. So far, benefits of trimetazidine in this group of patients have been suggested by clinical trials mainly conducted in Europe. We evaluated the effect of trimetazidine on ischemic dilated cardiomyopathy in our populati...
Autores principales: | Momen, A., Ali, M., Karmakar, P.K., Ali, M.Z., Haque, A., Khan, M.R., Khalil, M.I., Hossain, M.S., Huda, R.M., Goni, M.N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143824/ https://www.ncbi.nlm.nih.gov/pubmed/27931552 http://dx.doi.org/10.1016/j.ihj.2016.03.021 |
Ejemplares similares
-
Metabolic manipulation in Dilated Cardiomyopathy: assessing the role of trimetazidine
por: Kapoor, Aditya, et al.
Publicado: (2015) -
Metabolic manipulation in dilated cardiomyopathy: Assessing the role of trimetazidine
por: Jatain, Suman, et al.
Publicado: (2016) -
Histopathological Aspects of the Myocardium in Dilated Cardiomyopathy
por: MITRUT, R., et al.
Publicado: (2018) -
Meta-analysis of trimetazidine treatment for cardiomyopathy
por: Fan, Qian, et al.
Publicado: (2018) -
The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients
por: El-khodary, Noha M., et al.
Publicado: (2022)